Alector, Inc. (ALEC)

US — Healthcare Sector
Peers: PASG  BDTX  TCRR  HARP  RVMD  BCEL  STOK  FIXX  GLUE  CABA  LRMR 

Automate Your Wheel Strategy on ALEC

With Tiblio's Option Bot, you can configure your own wheel strategy including ALEC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ALEC
  • Rev/Share 0.8887
  • Book/Share 0.9518
  • PB 1.3973
  • Debt/Equity 0.4339
  • CurrentRatio 3.3401
  • ROIC -0.4754

 

  • MktCap 132990158.0
  • FreeCF/Share -2.3148
  • PFCF -0.578
  • PE -1.071
  • Debt/Assets 0.1005
  • DivYield 0
  • ROE -1.0058

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade ALEC Mizuho Outperform Neutral $9 $2.5 Dec. 17, 2024
Downgrade ALEC Stifel Buy Hold -- $4 Dec. 16, 2024
Downgrade ALEC BofA Securities Neutral Underperform $9 $1 Dec. 4, 2024

News

Alector to Participate in Upcoming Healthcare Conferences
ALEC
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m.

Read More
image for news Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
ALEC
Published: February 27, 2025 by: Seeking Alpha
Sentiment: Neutral

Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth …

Read More
image for news Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
ALEC
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Negative

Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago.

Read More
image for news Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates
Alector to Participate in Upcoming Healthcare Conferences
ALEC
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences:

Read More
image for news Alector to Participate in Upcoming Healthcare Conferences

About Alector, Inc. (ALEC)

  • IPO Date 2019-02-07
  • Website https://www.alector.com
  • Industry Biotechnology
  • CEO Dr. Arnon Rosenthal Ph.D.
  • Employees 175

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.